Inflammation and Cardiac Diseases

404 Pages·2003·8.642 MB·English

by  Giora Z. Feuerstein, Peter Libby, Douglas L. Mann (auth.), Giora Z. Feuerstein, Peter Libby, Douglas L. Mann (eds.)

Progress in Inflammation Research
Series Editor
Prof. Dr. Michael J. Parnham
PLIVA
Research Institute
Prilaz baruna Filipovica 25
10000 Zagreb
Croatia
Advisory Board
G. Z. Feuerstein (Merck Research Laboratories, West Point, PA, USA
W. van Eden (Universiteit Utrecht, Utrecht, The Netherlands)
Forthcoming titles:
Mind over Matter - Regulation of Peripheral Inflammation by the CNS,
C. Stein, M. Schaefer (Editors), 2003
Heat Shock Proteins and Inflammation, W. van Eden (Editor), 2003
Pharmacotherapy of Gl Inflammation, A. Guglietta (Editor), 2003
Arachidonate Remodeling and Inflammation, A.N. Fonteh, R.L. Wykle (Editor), 2003
Inflammation and Cardiac Diseases, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003
Inflammatory Processes and Cancer,
D. W. Morgan, U. Forssmann, M. Nakada (Editors), 2003
Recent Advances in Pathophysiology of COPD, P.J. Barnes, T.T. Hansel (Editors), 2003
Anti-Inflammatory or Anti-Rheumatic Drugs,
R.O. Day, D.E. Fürst, PL. van Riel (Editors), 2003
Cytokines and Joint Injury, P. Miossec, W.B. van den Berg (Editors), 2004
Antibiotics as Anti-lnflammatories, B. Rubin, J. Tamaoki (Editors), 2004
(Already published titles see last page.)
Inflammation and Cardiac Diseases
Giora Z. Feuerstein
Peter Libby
Douglas L. Mann
Editors
Springer Basel AG
Editors
Giora Z. Feuerstein Peter Libby
Pharmacology Department Cardiovascular Medicine
WP42-209, Brigham and Women's Hospital
Merck Research Laboratories 221 Longwood Avenue
770 Sumneytown Pike EBRC 307
West Point, PA 19486 Boston, MA 02115
USA USA
Douglas L. Mann
Winters Center for Heart Failure Research
6565 Fannin
MS 524
Houston, TX 77030
USA
A CIP catalogue record for this book is available from the Library of Congress, Washington D.C., USA
Bibliographic information published by Die Deutsche Bibliothek
Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie;
detailed bibliographic data is available in the internet at http://dnb.ddb.de
The publisher and editor can give no guarantee for the information on drug dosage and administration contained in
this publication. The respective user must check its accuracy by consulting other sources of reference in each individual
case.
The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that
they are exempt from the relevant protective laws and regulations or free for general use.
ISBN 978-3-0348-9419-7 ISBN 978-3-0348-8047-3 (eBook)
DOI 10.1007/978-3-0348-8047-3
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned,
specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on micro
films or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must
be obtained.
© 2003 Springer Basel AG
Originally published by Birkhäuser Verlag in 2003
Softcover reprint of the hardcover 1st edition 2003
Printed on acid-free paper produced from chlorine-free pulp. TCF »
Cover design: Markus Etterich, Basel
Cover illustration: Rat heart during the acute phase of myocarditis. Azan-Mallory staining. See chapter by
K. Watanabe et al. (With the friendly permission of K. Watanabe).
ISBN 978-3-0348-9419-7
987654321 www.birkhauser-science.com
Contents
List of contributors ix
Introduction
Giora Z. Feuerstein, Peter Libby and Douglas L. Mann
Inflammation - a new frontier in cardiac disease and therapeutics 1
Pathological aspects and inflammation biomarkers in cardiac diseases
Giora Z. Feuerstein, Ron Firestein, Douglas L. Mann and Peter Libby
A biomarker of inflammation in cardiovascular diseases .......... ............. 9
Renu Virmani, Frank D. Kolodgie, Allen P. Burke, Andrew Farb,
Herman K. Gold, Aloke V. Finn
Inflammation and coronary artery disease .............................. . 21
Inflammatory cells and their metalloproteinases in cardiac diseases
Esther E.J.M. Creemers, Jack P.M. Cleut;ens, Jos F.M. Smits and
Mat J.A. P. Daemen
The role of matrix metalloproteinases in LV remodeling following
myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Francis G. Spinale
Matrix metalloproteinases in heart failure: evidence from experimental
models. ......................................................................... 77
Inflammatory cytokines in cardiac diseases
Anita Deswal, Biykem Bozkurt and Douglas L. Mann
The clinical experience with anti-cytokine therapy in heart failure. . . . . . . . . . . . . . 95
Antoine Bril and Giora Feuerstein
The role of IL-6 and related cytokines in myocardial remodeling and
inflammation - implication for cardiac hypertrophy and heart failure .......... 111
Contents
Stefan Frantz, Ralph A. Kelly and Todd Bourcier
Toll-like receptors and the cardiovascular system ............................... 129
Elaine 1. Tanhehco and Hani N. Sabbah
The role of IL-6 in experimental and clinical heart failure ....................... 143
Oxygen and nitrogen reactive radicals in cardiac inflammation and disease
Flora Sam, Douglas B. Sawyer, Wilson S. Colucci
Myocardial nitric oxide in cardiac remodeling ................................... 155
Catherine Vergely, Gaelle Clermont, Sandrine Lecour, Antoine Bril
and Luc Rochette
Identification and role of inflammatory oxygen free radicals in
cardiac ischemia and reperfusion injury ......................................... 171
The immune and complement system and cardiac diseases
Kenichi Watanabe, Makoto Kodama, Yoshifusa Aizawa
Immune-mediated myocarditis and interleukin-10 .............................. 189
Shigetake Sasayama
Immunomodulation in heart failure: experimental models ...................... 203
Elaine 1. Tanhehco and Benedict R. Lucchesi
The role of complement in myocardial inflammation and
reperfusion injury ................................................................ 221
Inflammatory signaling pathways in cardiac diseases
Sandrine Lecour, Robert M. Smith, Michael N. Sack
The role of immune and inflammatory cytokines in ischemic
preconditioning of the heart - identification of novel cardiac cell
survival signaling programs ..................................................... 251
Masaya Tanno and Michael Marber
Stress-activated signals and their role in myocardial ischemia .................. . 271
Thomas M. Behr, Christopher P. Doe, Haisong lu and Robert N. Willette
p38 MAPK in cardiac remodeling and failure: cytokine signaling
and beyond . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 293
vi
Contents
Inflammation and myocarditis
Jay W Mason
Inflammation and myocarditis ............. . 315
Noel R. Rose and Marina Afanasyeva
The inflammatory process in experimental myocarditis .... 325
Nuclear factors in cardiac disease
Quy N. Diep, Farhad Amiri and Ernesto L. Schiffrin
Peroxisome proliferator activated receptors, inflammation, the vasculature
and the heart . . . . . . . . . . . . . . . . . 337
Chemokines and cardiac diseases
Joseph Winaver, Thomas M. Behr and Zaid Abassi
Role of chemokines in the pathogenesis of congestive heart failure ... . ... 351
Neurohormonal mediators and cardiac inflammation
Li L. Yang, Mansoor Husain and Duncan 1. Stewart
The role of endothelin-1 in myocardial inflammation and fibrosis ...... 371
Cyclooxygenases and cardiac diseases
Gary F. Baxter and Caroline P.O. Wheeler-Jones
Cyclo-oxygenase-2 and myocardial ischemia .......... 387
Inflammation and arrhythmias
David R. Van Wagoner and Mina K. Chung
Inflammation as a cause and consequence of atrial fibrillation 399
Giora Z. Feuerstein, Peter Libby, Douglas L. Mann
Summary: Immune and inflammatory modulators as potential
therapeutic targets for cardiac diseases 407
Index 411
vii
List of contributors
Zaid Abassi, Department of Physiology & Biophysics, Faculty of Medicine, Tech
nion Medical School, P.o. Box 9649, Haifa 31096, Israel;
e-mail: [email protected]
Marina Afanasyeva, Immunology Research Group, Department of Physiology and
Biophysics, University of Calgary Health Sciences Center, 3330 Hospital Drive, Cal
gary, AB T2N 4N1, Canada; e-mail: [email protected]
Yoshifusa Aizawa, First Department of Medicine, Niigata University School of
Medicine, Asahimachi, Niigata 951-8510, Japan; e-mail: [email protected]
Farhad Amiri, University of Montreal, CIHR Multidisciplinary Research Group on
Hypertension, Clinical Research of Montreal, 110 avenue des Pins ouest, Montreal,
PQ Canada H2W 1R7; e-mail: [email protected]
Gary F. Baxter, Infection, Inflammation and Vascular Biology Research Group,
Department of Basic Sciences, The Royal Veterinary College, University of London,
Royal College Street, London NW1 OTU, UK; e-mail: [email protected]
Thomas M. Behr, Department of Cardiology, Medizinische Poliklinik, University of
Wiirzburg, Klinikstrasse 6, 97084 Wiirzburg, Germany;
e-mail: [email protected]
Todd Bourcier, Cardiovascular Division, Brigham and Women's Hospital, 75 Fran
cis Street, Boston, MA 02115, USA; e-mail: [email protected]
Biykem Bozkurt, Winters Center for Heart Failure Research, the Cardiology Sec
tion, Department of Medicine, Veterans Administration Medical Center and Baylor
College of Medicine, 6565 Fannin, Houston, TX 77030, USA
Antoine Bril, Institut de Recherches Servier, 11 rue des Moulineaux, F-92150
Suresnes, France; e-mail: [email protected]
ix
List of contributors
Allen P. Burke, Department of Cardiovascular Pathology, Armed Forces Institute of
Pathology, 6825 16th St. NW, Washington, DC 20306-6000, USA;
e-mail: [email protected]
Gaelle Clermont, Biomatech, ZI de l'Islon, Rue Pasteur, 38670 Chasse-Sur-Rhone,
France; e-mail: [email protected]
Jack P. M. Cleutjens, Department of Pathology, Cardiovascular Research Institute
Maastricht (CARIM), University of Maastricht, PO Box 616, 6200 MD Maastricht,
The Netherlands
Wilson S. Colucci, Cardiovascular Medicine, Boston University Medical Center, 88
East Newton St., D-8, Boston MA 02118, USA; e-mail: [email protected]
Esther E. J. M. Creemers, Department of Pathology, Cardiovascular Research Insti
tute Maastricht (CARIM), University of Maastricht, PO Box 616,6200 MD Maas
tricht, The Netherlands; e-mail: [email protected]
Mat J,A.P. Daemen, Department of Pathology, University of Maastricht, Cardio
vascular Research Institute Maastricht (CARIM), University of Maastricht, PO Box
616,6200 MD Maastricht, The Netherlands; e-mail: [email protected]
Anita Deswal, Cardiology Research (151C), Winters Center for Heart Failure
Research, VA Medical Center, 2002 Holocombe Blvd, Houston, TX 77030, USA
Quy N. Diep, University of Montreal, CIHR Multidisciplinary Research Group on
Hypertension, Clinical Research of Montreal, 110 avenue des Pins Ouest, Montre
al, PQ Canada H2W 1R7; e-mail: [email protected]
Christopher P. Doe, Department of Investigative and Cardiac Biology, Glaxo
SmithKline, 709 Swedeland Rd, King of Prussia, PA 19406-0939, USA;
e-mail: [email protected]
Andrew Farb, Department of Cardiovascular Pathology, Armed Forces Institute of
Pathology, 6825 16th St. NW, Washington, DC 20306-6000, USA;
e-mail: [email protected]
Giora Z. Feuerstein, Pharmacology Department, WP42-209, Merck Research Lab
oratories, 770 Sumneytown Pike, West Point, PA 19486, USA;
e-mail: [email protected]
x
List of contributors
Aloke V. Finn, Massachusetts General Hospital, Bigalow 800, 55 Fruit Street,
Boston, MA 02114, USA; [email protected]
Stefan Frantz, Medizinische Universitatsklinik Wiirzburg, Josef-Schneider-Str. 2,
97080 Wiirzburg, Germany; e-mail: [email protected]
Herman K. Gold, Massachusetts General Hospital, Bigalow 800, 55 Fruit Street,
Boston, MA 02114, USA; [email protected]
Mansoor Husain, Heart and Stroke Richard Lewar Centre of Excellence, Universi
ty of Toronto, Ontario, Canada; e-mail: [email protected]
Haisong Ju, Department of Investigative and Cardiac Biology, GlaxoSmithKline,
709 Swedeland Rd, King of Prussia, PA 19406, USA;
e-mail: [email protected]
Ralph Kelly, Genzyme Corporation, 15 Pleasant St, Connector, P.O. Box 9322,
Framingham, MA 01701-9322, USA; e-mail: [email protected]
Makoto Kodama, First Department of Medicine, Niigata University of School of
Medicine, Asahimachi, Niigata 951-8510, Japan;
e-mail: [email protected]
Frank D. Kolodgie, Department of Cardiovascular Pathology, Armed Forces Insti
tute of Pathology, 6825 16th St. NW, Washington, DC 20306-6000, USA;
e-mail: [email protected]
Sandrine Lecour, Laboratoire de Physiopathologie et Pharmacologie Cardiovascu
laires Experimentales, IFR 100, Facultes de Medecine et Pharmacie, Universite de
Bourgogne, 7 Bd. Jeanne d'Arc-BP 87900, 21079 Dijon, France, and Hatter Insti
tute for Cardiology Research, UCT Medical School, Cape Town, 7925, South
Africa; e-mail: [email protected]
Peter Libby, Cardiovascular Medicine, Brigham and Women's Hospital, Professor of
Medicine, Harvard Medical School, Brigham and Women's Hospital, 221 Long
wood Avenue, EBRC 307, Boston, MA 02115;
e-mail: [email protected]
Benedict Lucchesi, University of Michigan Medical School, Department of Pharma
cology, 1301C Medical Sciences Research Building III, 1150 W. Medical Center
Drive, Ann Arbor MI 48109-0632, USA; e-mail: [email protected]
xi